Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials

AIMS: Heart failure with reduced ejection fraction (HFrEF) remains associated with high morbidity and mortality, poor quality of life (QoL) and significant exercise limitation. Sympatho‐vagal imbalance has been shown to predict adverse prognosis and symptoms in HFrEF, yet it has not been specificall...

Descripción completa

Detalles Bibliográficos
Autores principales: Coats, Andrew J.S., Abraham, William T., Zile, Michael R., Lindenfeld, Joann A., Weaver, Fred A., Fudim, Marat, Bauersachs, Johann, Duval, Sue, Galle, Elizabeth, Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Devices
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796660/
https://www.ncbi.nlm.nih.gov/pubmed/35713888
http://dx.doi.org/10.1002/ejhf.2573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796660/
https://www.ncbi.nlm.nih.gov/pubmed/35713888
http://dx.doi.org/10.1002/ejhf.2573

Ejemplares similares